The estimated Net Worth of Yann Echelard is at least $6.09 Milion dollars as of 6 January 2023. Mr. Echelard owns over 9,000 units of TG Therapeutics Inc stock worth over $4,656,633 and over the last 12 years he sold TGTX stock worth over $1,201,500. In addition, he makes $235,000 as Independent Director at TG Therapeutics Inc.
Yann has made over 2 trades of the TG Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of TGTX stock worth $95,760 on 6 January 2023.
The largest trade he's ever made was selling 30,000 units of TG Therapeutics Inc stock on 10 December 2020 worth over $1,201,500. On average, Yann trades about 2,786 units every 54 days since 2013. As of 6 January 2023 he still owns at least 201,848 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Echelard stock trades at the bottom of the page.
Dr. Yann Echelard serves as Independent Director of the Company. Dr. Echelard, current Operating Partner at Flagship Pioneering, has over 25 years of research and biopharmaceutical experience. Dr. Echelard holds a Ph.D. from Université de Montréal, and has completed post-doctoral studies at Ludwig Institute of Cancer Research in Montreal (McGill University). As a visiting scientist at the Roche Institute and at Harvard University (Developmental Biology), he had a key role in the isolation and characterization of the Hedgehog genes, the first identified vertebrate morphogens. From 1994 to 2010, he progressed through various positions of increasing responsibility at Genzyme Transgenics Corporation and at GTC Biotherapeutics, including Vice President of Research and Development. In 1998, he led the scientific team that first performed goat somatic cell nuclear transfer (cloning). Focusing on Corporate Development, Dr. Echelard spearheaded the creation of a collaborative Joint Venture with LFB Biotechnologies in 2006, which was focused on the development of recombinant plasma proteins and monoclonal antibodies. This close collaboration led to the acquisition of GTC Biotherapeutics, Inc. by LFB in December 2010. In January of 2013, Dr. Echelard became the President and Chief Executive Officer of EVO Biologics, the successor of GTC Biotherapeutics, Inc., a position he held until April 2018. Based on Mr. Echelard’s biotechnology and pharmaceutical industry experience, as well as his extensive management experience, the Board of Directors believes that Mr. Echelard has the appropriate set of skills to serve as a member of the Board.
As the Independent Director of TG Therapeutics Inc, the total compensation of Yann Echelard at TG Therapeutics Inc is $235,000. There are 6 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.
Yann Echelard is 56, he's been the Independent Director of TG Therapeutics Inc since 2012. There are 2 older and 7 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
Yann's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.
Over the last 13 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss oraz Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
TG Therapeutics Inc executives and other stock owners filed with the SEC include: